6月3日，阿斯利康盘前下跌3.18%，报171.94美元/股，成交额57.72万美元。
消息面上，公司旗下Alexion罕见病部门此前披露，评估anselamimab治疗轻链淀粉样变性的CARES III期临床项目在总体患者人群中未达到主要终点。尽管预设Kappa亚组显示全因死亡率改善62%、心血管住院率降低71%，但整体数据未能达标，构成管线层面利空。该消息自公布以来持续压制股价，公司已连续多个交易日走低。当前制药板块同业表现相对平稳，礼来涨0.1%、强生涨0.11%、默沙东涨0.2%，阿斯利康跌幅明显超出行业整体水平，反映市场对其管线风险的持续定价。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.